BRIEF published on 07/23/2026 at 16:01, 19 days 16 hours ago ABL Diagnostics falls below the 95% threshold Growth Strategy Stock Liquidity Majority Shareholder ABL Diagnostics Widening Of The Floating
BRIEF published on 07/23/2026 at 09:27, 19 days 23 hours ago ABL Diagnostics takes over TEXCELL's activities Investment ABL Diagnostics Virology Genopole TEXCELL Takeover
PRESS RELEASE published on 07/23/2026 at 09:22, 19 days 23 hours ago Inside Information / Other news releases ABL Diagnostics selected by the \u00c9vry Commercial Court to acquire TEXCELL's operations, enhancing life sciences and infectious diseases activities at Genopole Acquisition Molecular Diagnostics ABL Diagnostics Genopole TEXCELL
BRIEF published on 07/13/2026 at 08:05, 30 days ago Half-yearly review of the ABL Diagnostics Liquidity Contract in 2026 Liquidity Contract Stock Market Transactions ABL Diagnostics Half-year Review First Half Of 2026
BRIEF published on 06/18/2026 at 13:57, 1 month 23 days ago ABL Diagnostics: Growth and Outlook for 2026 INVEST SECURITIES Growth Partnerships Molecular Diagnosis Genotyping
BRIEF published on 06/18/2026 at 13:57, 1 month 23 days ago ABL Diagnostics Projects Notable Growth and Upward Potential Strategic Partnerships Revenue Increase Buy Recommendation ABL Diagnostics Growth 2026
PRESS RELEASE published on 06/18/2026 at 13:52, 1 month 23 days ago Inside Information / Other news releases ABL Diagnostics confirms growth trajectory with strong upside potential. Invest Securities raises target price to €8.7 and maintains 'Buy' recommendation INVEST SECURITIES Target Price Growth Trajectory Upside Potential ABL Diagnostics
BRIEF published on 06/12/2026 at 08:05, 2 months ago ABL Diagnostics and CDL Pharma Secure €2.7 Million Contract Clinical Program Neurodegenerative Diseases International Contract ABL Diagnostics CDL Pharma
BRIEF published on 06/12/2026 at 08:05, 2 months ago ABL Diagnostics and CDL Pharma sign a €2.7 million contract until 2031 Clinical Trials Neurodegenerative Diseases ABL Diagnostics Multi-year Contract CDL Pharma
PRESS RELEASE published on 06/12/2026 at 08:00, 2 months ago Inside Information / Other news releases ABL Diagnostics and CDL Pharma secure a multi-year international contract of up to €2.7 million through 2031. The contract involves services for neurodegenerative disease clinical programs across North America, Europe, and Asia Neurodegenerative Diseases ABL Diagnostics Multi-year Contract CDL Pharma International Clinical Program
Published on 08/12/2026 at 08:02, 27 minutes ago Southern Energy Corp. Announces Spudding of Cotton Valley Test Well at Williamsburg and Appointment of Market Maker
Published on 08/12/2026 at 08:00, 29 minutes ago Galantas Selects Engineering and Mine Planning Contractors for Andacollo Gold Project
Published on 08/12/2026 at 00:00, 8 hours 29 minutes ago Organto Foods Reports Record Second Quarter 2026 Financial Results
Published on 08/11/2026 at 23:40, 8 hours 49 minutes ago RJK Explorations Ltd. Announces Private Placement for Gross Proceeds of up to $100,000
Published on 08/11/2026 at 23:15, 9 hours 14 minutes ago Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador
Published on 08/12/2026 at 08:11, 18 minutes ago hGears Group achieved results in line with expectations in the first half of 2026 and confirms the guidance
Published on 08/12/2026 at 08:05, 24 minutes ago Zurich Group Germany Accelerates Digital Transformation with Move to Guidewire Cloud
Published on 08/12/2026 at 08:00, 29 minutes ago Viscom SE increases order intake by 30% in the first half of 2026 – Significant rise in the order book lays a solid foundation for the second half of the year; full-year forecast for 2026 confirmed
Published on 08/12/2026 at 07:57, 32 minutes ago Medios continues growth path in the first half of 2026 and focuses on profitability and cash conversion
Published on 08/12/2026 at 07:45, 44 minutes ago Delignit AG reports significant increase in revenue and earnings in the first half of 2026 and confirms its guidance
Published on 08/10/2026 at 18:00, 1 day 14 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 1 day 20 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 1 day 20 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 1 day 23 hours ago Number of shares and voting rights - July 2026 (In French only)
